March 19, 2014
CTI Clinical Trial and Consulting Services Presented at The Transplant Society Workshop
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ March 19, 2014] CTI Clinical Trial and Consulting Services (CTI) Chief Executive Officer, Timothy J. Schroeder, presented at The Transplant Society “International Workshop for Clinical Tolerance”, that took place in Boston, MA, March 14-15.
The goals of the workshop, according to The Transplant Society, included discussions of what needs to be in place to make tolerance induction protocols a “standard of care” for kidney transplant recipients over the next decade. Leading academic authorities joined with members of the National Institute of Health (NIH) and the Food and Drug Administration (FDA) to discuss and design research approaches for optimizing tolerance protocols for kidney transplant recipients, eliminating the need for potentially damaging immunosuppressant medications.
Mr. Schroeder presented on the topic “Infrastructure and Costs of Multi-Center Trials of Tolerance Induction”. According to Mr. Schroeder, “We are proud to join this distinguished group, who have worked for many years to move the field of transplantation to where it is today. We are very optimistic that future advances in kidney transplantation will include tolerance approaches.”
Mr. Schroeder founded CTI fifteen years ago, and is internationally recognized in the field of transplantation and regenerative medicine. Throughout his more than 30 years of clinical, academic, and industry experience, he has authored over 200 peer reviewed publications and has presented more than 300 papers at national and international conferences. He has served as a visiting lecturer on more than 200 occasions.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.